GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Deciphera Pharmaceuticals Inc (NAS:DCPH) » Definitions » Volatility

Deciphera Pharmaceuticals (Deciphera Pharmaceuticals) Volatility : 40.35% (As of Apr. 27, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Deciphera Pharmaceuticals Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2024-04-27), Deciphera Pharmaceuticals's Volatility is 40.35%.


Competitive Comparison of Deciphera Pharmaceuticals's Volatility

For the Drug Manufacturers - Specialty & Generic subindustry, Deciphera Pharmaceuticals's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Deciphera Pharmaceuticals's Volatility Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Deciphera Pharmaceuticals's Volatility distribution charts can be found below:

* The bar in red indicates where Deciphera Pharmaceuticals's Volatility falls into.



Deciphera Pharmaceuticals  (NAS:DCPH) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Deciphera Pharmaceuticals  (NAS:DCPH) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


Deciphera Pharmaceuticals Volatility Related Terms

Thank you for viewing the detailed overview of Deciphera Pharmaceuticals's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


Deciphera Pharmaceuticals (Deciphera Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
200 Smith Street, Waltham, MA, USA, 02451
Deciphera Pharmaceuticals Inc is a biotechnology company, which develops and manufactures kinase-inhibiting drugs for the treatment of cancers and immunological diseases. It holds a diverse pipeline of drug candidates that includes three clinical-stage and two research-stage programs. Its lead drug candidate DCC-2618 is designed to inhibit the full spectrum of mutant or amplified KIT and Pdgfra kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. In addition, it is also developing two other clinical-stage drug candidates, DCC-3014 and Rebastinib. Geographically all the operations function through the region of the United States.
Executives
Jama Pitman officer: SVP, Regulatory & Quality C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Daniel C. Martin officer: Chief Commercial Officer C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Thomas Patrick Kelly officer: Chief Financial Officer C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Matthew L Sherman officer: EVP & Chief Medical Officer C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Steven L. Hoerter director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Dashyant Dhanak officer: EVP & Chief Scientific Officer C/O INCYTE CORPORATION, 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Daniel Lee Flynn officer: Chief Scientific Officer C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Franklin Stuart Friedman director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Dennis Leo Walsh director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Brightstar Associates Llc 10 percent owner 1020 CENTRAL STREET, KANSAS CITY MO 64105
James Arthur Bristol director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Michael Douglas Taylor director, officer: See Remarks C/O DECIPHERA PHARMACEUTICALS, LLC, 500 TOTTEN POND ROAD, WALTHAM MA 02451
Patricia L Allen director C/O DECIPHERA PHARMACEUTICALS, INC, 200 SMITH STREET, WALTHAM MA 02451
Christopher John Morl officer: Chief Business Officer C/O DECIPHERA PHARMACEUTICALS, LLC, 500 TOTTEN POND ROAD, WALTHAM MA 02451
Ron Squarer director C/O ADC THERAPEUTICS SA, BIOPOLE, ROUTE DE LA CORNICHE 3B, EPALINGES V8 1066

Deciphera Pharmaceuticals (Deciphera Pharmaceuticals) Headlines

From GuruFocus